Latest Content

In the latest episode of The Independent Advantage, Maria Sampalis, OD, gives a resounding "absolutely not" when posited with the question of whether or not eye care providers will be replaced by AI.

A recent study found that migraines were associated with higher adverse vision outcomes in a cohort of Norwegian adolescents.

Jem Martin, OD, discusses the accommodations and referrals any provider can offer, the red flags that should raise suspicion of CVI, and how the free TEACHCVI screening tool works in practice.

AMA resolution backs classifying myopia as a disease, aiming to expand insurance coverage for pediatric myopia control treatments.

Optometrists should know what is expected, what is concerning, and when to contact the surgeon.

Catch up on the top stories in optometry during the week of September 7-September 11.

Startup S5G Therapeutics aims to move ubiquinol technology from the laboratory toward treatments for dry eye, Fuchs dystrophy, and other corneal conditions.

Mogenry (sonpiretigene isteparvovec, MC-010) is a gene therapy for retinitis pigmentosa with severe vision loss.

Heru's PretestPro runs 4 pretesting exams in about 90 seconds on the Heru Prime wearable platform and reaches all current and future customers via free software update.

The latest in drug and technology developments and updates from August 2026.

Merabet, OD, PhD, MPH, discusses what his research on motion processing reveals about the neural roots of CVI and where diagnostic tools like neuroimaging and eye tracking are headed.

Host Hamza Shah, OD, MS, FAAO, is joined by Leonard Messner, OD, to discuss GLP-1s and idiopathic intracranial hypertension, inspired by Mitchell et al's paper, "The Effect of GLP-1RA Exenatide on Idiopathic Intracranial Hypertension: A Randomized Clinical Trial."

Periocular skin treatment is emerging as a complementary treatment for dry eye disease.